Ligand Pharmaceuticals (LGND) Total Liabilities (2010 - 2026)

Ligand Pharmaceuticals has disclosed Total Liabilities across 17 years of filings, most recently posting $534.8 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $534.8 million, up 386.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $534.8 million (up 386.6% YoY), and the FY2025 annual result was $543.4 million, up 388.1% from the prior year.
• Total Liabilities came in at $534.8 million for Q1 2026 at Ligand Pharmaceuticals, down from $543.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $543.4 million in Q4 2025 to a low of $86.3 million in Q4 2023.
• The 5-year median for Total Liabilities is $120.1 million (2025), against an average of $217.0 million.
• Across the five-year window, Total Liabilities slumped 65.97% in 2023 and jumped 388.1% in 2025, its largest moves.
• Ligand Pharmaceuticals' Total Liabilities stood at $165.2 million in 2022, then tumbled by 47.75% to $86.3 million in 2023, then increased by 29.0% to $111.3 million in 2024, then surged by 388.1% to $543.4 million in 2025, then fell by 1.59% to $534.8 million in 2026.
• The last three Total Liabilities figures came in at $534.8 million (Q1 2026), $543.4 million (Q4 2025), and $526.6 million (Q3 2025), per Business Quant data.